MYL2 Monoclonal Antibody

Thus gene encodes the regulatory light chain associated with cardiac myosin beta (or slow) heavy chain. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in this gene are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy.

Introducing the MYL2 Monoclonal Antibody, a cutting-edge biotechnological product designed to revolutionize the field of medical research and diagnostics. This meticulously crafted antibody is specifically engineered to target and bind to the MYL2 protein, a crucial component of cardiac muscle contraction.

With utmost precision and accuracy, the MYL2 Monoclonal Antibody offers unparalleled sensitivity and specificity, enabling researchers and clinicians to delve deeper into the intricate mechanisms underlying cardiac function. Its exceptional affinity for the MYL2 protein ensures reliable and reproducible results, facilitating a comprehensive understanding of cardiac pathophysiology.

Crafted using state-of-the-art techniques, the MYL2 Monoclonal Antibody guarantees exceptional quality and consistency, meeting the rigorous standards demanded by the scientific community. Its robust formulation ensures long-term stability, allowing for extended storage without compromising its efficacy.

The MYL2 Monoclonal Antibody's versatility extends beyond research applications, as it also serves as a valuable tool in diagnostic settings. Its ability to accurately detect and quantify MYL2 protein levels in patient samples enables early identification and monitoring of cardiac disorders, paving the way for timely intervention and improved patient outcomes.

Incorporating the MYL2 Monoclonal Antibody into your research or diagnostic endeavors promises to unlock new insights and advancements in the realm of cardiac biology. Embrace the power of precision and reliability with the MYL2 Monoclonal Antibody, and elevate your scientific pursuits to unprecedented heights.